VANIQA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VANIQA (VANIQA).
Irreversible inhibitor of ornithine decarboxylase, reducing polyamine synthesis and decreasing hair growth.
| Metabolism | Not extensively metabolized; minor hepatic metabolism via unknown pathways. |
| Excretion | Renal: ~44% as unchanged drug; biliary/fecal: minimal (not systematically studied in humans; based on animal data, ~33% fecal). |
| Half-life | Terminal elimination half-life: Approximately 8 hours (range 6-10 hours) following topical application; clinical context: supports twice-daily application. |
| Protein binding | Not determined; eflornithine does not bind significantly to plasma proteins (estimated <10% based on physicochemical properties). |
| Volume of Distribution | Not systematically reported for topical VANIQA; systemic absorption after topical application is low (<1% of applied dose); Vd not calculated. |
| Bioavailability | Topical: Systemic bioavailability <1% (based on urinary excretion of unchanged drug). Oral: Not applicable (VANIQA is topical only). |
| Onset of Action | Topical: Clinical effect (reduction of facial hair growth) typically observed after 4-8 weeks of twice-daily use. |
| Duration of Action | Topical: Growth reduction persists with continued use; hair regrowth returns to baseline within 8 weeks after discontinuation. |
Apply a thin layer of 13.9% cream to affected areas of face and adjacent chin twice daily, at least 8 hours apart.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients below 12 years have not been established. |
| Geriatric use | No specific dosage adjustment recommended; use caution due to potential age-related renal and hepatic function decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VANIQA (VANIQA).
| Breastfeeding | Unknown if excreted in human breast milk. Due to potential for serious adverse reactions in nursing infants, caution is advised; consider importance of drug to mother and discontinue nursing or drug. |
| Teratogenic Risk | Pregnancy Category C. Animal studies have shown teratogenic effects at doses equivalent to human exposure, but no adequate human studies. Risk cannot be ruled out; use only if clearly needed and benefit outweighs potential fetal risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to eflornithine or any component of the formulation"]
| Precautions | ["May cause local skin irritation (e.g., redness, burning, stinging)","Avoid contact with eyes, mouth, and mucous membranes","Not studied in men or children"] |
Loading safety data…
| Monitor for maternal adverse effects (e.g., skin irritation, hearing loss) and fetal growth via ultrasound if used during pregnancy. |
| Fertility Effects | No significant fertility impairment observed in animal studies; no human data. |